Discovery of new heart failure trigger could change the way cardiovascular drugs are made
APJ's yin-yang role in cardiac function: the receptor APJ serves a dual function in heart health, depending on how it’s activated. While APJ enhances heart health upon binding the hormone apelin (green), APJ can also trigger heart enlargement and failure when it senses certain mechanical changes (red). Credit: Sanford-Burnham Medical Research Institute
In their quest to treat cardiovascular disease, researchers and pharmaceutical companies have long been interested in developing new medicines that activate a heart protein called APJ. But researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) and the Stanford University School of Medicine have now uncovered a second, previously unknown, function for APJit senses mechanical changes when the heart is in danger and sets the body on a course toward heart failure. This means that activating APJ could actually be harmful in some casespotentially eye-opening information for some heart drug makers. The study appears July 18 in Nature.
"Just finding a molecule that activates APJ is not enough. What's important to heart failure is not if this receptor is 'on' or 'off,' but the way it's activated," said Pilar Ruiz-Lozano, Ph.D., who led the study. Ruiz-Lozano, formerly assistant professor at Sanford-Burnham, is now associate professor of pediatrics in the Stanford University School of Medicine and adjunct faculty member at Sanford-Burnham.
Stretching the heart
APJ is a receptor that sits on the cell surface in many organs, where it senses the external environment. When a hormone called apelin comes along and binds APJ, it sets off a molecular chain reaction that influences a number of cellular functions. Many previous studies have shown that apelin-APJ activity directs beneficial processes such as embryonic heart development, maintenance of normal blood pressure, and new blood vessel formation.
According to Ruiz-Lozano's latest study, however, APJ can also be activated a second, more harmful, way that doesn't involve apelin. In this pathway, APJ senses and responds to mechanical changes in the heart.
To better understand these mechanical changes, let's look at a person with high blood pressure. In this case, the person's heart has to work harder to pump the same amount of blood at the same rate as a healthy person. To meet the increased demand, individual heart muscle cells start making more proteins, making the cells bigger. Eventually, cell membranes stretch and each cell begins to pull away from its neighbor. This leads to an enlarged hearta condition known as hypertrophy. In pathological (disease) conditions, hypertrophy can lead to heart failure.
APJ and heart failure
The best way to determine the role a protein plays in a particular cellular process is to see what happens when it's missing. To do this, Ruiz-Lozano's team, including co-first authors Maria Cecilia Scimia, Ph.D. and Cecilia Hurtado, Ph.D., used mice that lack APJ. Under everyday conditions, the APJ-deficient mice appeared perfectly normal. However, unlike their normal counterparts, the mice lacking APJ couldn't sense danger when their hearts enlarged. As a result, mice were actually healthier without APJnone succumbed to heart failure.
"In other words, without APJ, ignorance is blissthe heart doesn't sense the danger and so it doesn't activate the hypertrophic pathways that lead to heart failure," Ruiz-Lozano said. "This tells us that, depending on how it's done, activating APJ might make matters worse for heart disease patients."
Journal reference:
Nature
Provided by
Sanford-Burnham Medical Research Institute
-
Understanding the APJ Receptor Binding Site
Jun 01, 2010 |
not rated yet |
0
-
Study finds fat hormone's long-sought link to heart protection
Nov 01, 2010 |
not rated yet |
0
-
Impaired activity of the protein MTOR a strain on the heart
Jul 19, 2010 |
not rated yet |
0
-
Taking vitamin E does not impact women's heart failure risk
Mar 20, 2012 |
not rated yet |
0
-
Heart hormone helps shape fat metabolism
Feb 06, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
what is the distance traveled
59 minutes ago
-
Image of a Convex Lens Cut in Half Horizontally
4 hours ago
-
Ray tracing throught optical system of thick lenses
5 hours ago
-
Faraday's law on circular wire
5 hours ago
-
Specific Exergy vs Specific Flow Exergy
7 hours ago
-
The Durability of Bone: Long Falls
15 hours ago
- More from Physics Forums - Classical Physics
More news stories
Costs to treat stroke in America may double by 2030
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology
1 hour ago |
not rated yet |
0
New blood-thinner measures may cut medication errors
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology
4 hours ago |
not rated yet |
0
Registry questions superiority of bivalirudin over heparin
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...
Cardiology
4 hours ago |
not rated yet |
0
Study shows low rate of late lumen loss with bioresorbable DESolve device
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...
Cardiology
4 hours ago |
not rated yet |
0
Biodegradable stent proves non-inferior to drug-eluting stent
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
Cardiology
20 hours ago |
5 / 5 (1) |
0
Researchers complete largest genetic sequencing study of human disease
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
Slowing the aging process—only with antibiotics
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
Research shows how immune system peacefully co-exists with 'good' bacteria
The human gut is loaded with commensal bacteria – "good" microbes that, among other functions, help the body digest food. The gastrointestinal tract contains literally trillions of such cells, and yet the ...
AIDS scientists optimistic of AIDS cure, for some
Top AIDS scientists were optimistic Wednesday of finding a cure for the disease that has claimed 30 million lives—but said it might not work for all people.
Fish oil supplements may help fight against Type 2 diabetes
Widely-used fish oil supplements modestly increase amounts of a hormone that is associated with lower risk of diabetes and heart disease, according to a study accepted for publication in The Endocrine Society's Journal of ...
Fish oil may help the heart beat mental stress
Why is fish oil good for the heart? A new study suggests that this omega 3 fatty acid-rich nutrient could blunt some cardiovascular effects of mental stress.